<DOC>
	<DOC>NCT01527500</DOC>
	<brief_summary>The amendment is designed to test the safety and efficacy of lower and higher doses of Intravitreal (IVT) LFG316 using single and 18 successive monthly injections in patients with geographic atrophy (GA). The study will also provide information on the safety, tolerability, serum concentrations and pharmacodynamics of single and multiple IVT doses of LFG316.</brief_summary>
	<brief_title>Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Diagnosis of AMD Geographic atrophy in at least one eye ETDRS best corrected visual acuity of 60 letters or worse (~â‰¤ 20/63) Retinal disease other than AMD History of choroidal neovascularization Severe cataract History of infectious uveitis or endophthalmitis Eye surgery in the nonstudy eye within 30 days prior to study Eye surgery or IVT injection in the study eye within 90 days prior to study Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>AMD</keyword>
	<keyword>Age-related Macular Degeneration</keyword>
	<keyword>geographic atrophy</keyword>
	<keyword>GA</keyword>
	<keyword>Dry AMD</keyword>
	<keyword>Blindness</keyword>
	<keyword>Drusen</keyword>
	<keyword>GA lesion</keyword>
</DOC>